Baxter International has collaborated with Chatham Therapeutics for the development and commercialization of factor IX hemophilia B gene therapy treatment. According to the agreement, the companies will investigate the next generation of ...
Tags: IX hemophilia B gene therapy, Biological Nano Particles, clinical trials